Free Trial
→ Read this or regret it forever (From Porter & Company) (Ad)tc pixel Free OLMA Stock Alerts

Olema Pharmaceuticals (OLMA) Financials

Olema Pharmaceuticals logo
$13.82 +0.24 (+1.77%)
Closing price 04:00 PM Eastern
Extended Trading
$13.61 -0.21 (-1.53%)
As of 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Olema Pharmaceuticals

Annual Income Statements for Olema Pharmaceuticals

This table shows Olema Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.32 -24 -71 -105 -97 -129 -162
Consolidated Net Income / (Loss)		 -4.32 -22 -71 -105 -97 -129 -162
Net Income / (Loss) Continuing Operations		 -4.32 -22 -71 -105 -97 -129 -162
Total Pre-Tax Income 		-4.32 -22 -71 -105 -97 -129 -162
Total Operating Income		 -4.32 -22 -71 -107 -105 -142 -179
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 4.32 22 71 107 105 142 179
Selling, General & Admin Expense		 0.40 7.82 20 25 19 18 21
Research & Development Expense		 3.92 14 51 82 86 125 158
Total Other Income / (Expense), net		 0.01 -0.59 0.40 2.20 8.31 13 16
Interest & Investment Income		 0.01 0.06 0.44 2.23 8.33 13 16
Other Income / (Expense), net		 0.00 0.00 -0.05 -0.03 -0.02 0.10 0.02
Basic Earnings per Share		 ($1.66) ($3.42) ($1.80) ($2.62) ($2.14) ($2.20) ($1.87)
Weighted Average Basic Shares Outstanding		 2.59M 7.02M 39.52M 40.00M 45.25M 58.74M 87.01M
Diluted Earnings per Share		 ($1.66) ($3.42) ($1.80) ($2.62) ($2.14) ($2.20) ($1.87)
Weighted Average Diluted Shares Outstanding		 2.59M 7.02M 39.52M 40.00M 45.25M 58.74M 87.01M
Weighted Average Basic & Diluted Shares Outstanding		 - - 40.35M 40.63M 55.91M 68.33M 87.16M

Quarterly Income Statements for Olema Pharmaceuticals

This table shows Olema Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -22 -27 -31 -30 -35 -34 -30 -44 -42 -46 -53
Consolidated Net Income / (Loss)		 -22 -27 -31 -30 -35 -34 -30 -44 -42 -46 -53
Net Income / (Loss) Continuing Operations		 -22 -27 -31 -30 -35 -34 -30 -44 -42 -46 -53
Total Pre-Tax Income 		-22 -27 -31 -30 -35 -34 -30 -44 -42 -46 -53
Total Operating Income		 -23 -30 -34 -34 -38 -37 -35 -48 -46 -50 -58
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 23 30 34 34 38 37 35 48 46 50 58
Selling, General & Admin Expense		 3.89 4.54 4.46 4.42 4.40 4.47 4.25 3.96 5.93 6.86 8.75
Research & Development Expense		 19 26 30 29 33 32 31 44 40 43 49
Total Other Income / (Expense), net		 1.84 3.64 3.37 3.15 3.07 3.20 4.48 4.08 3.66 4.02 4.90
Interest & Investment Income		 1.92 3.55 3.35 3.11 2.93 3.29 4.52 4.04 3.65 4.01 4.78
Other Income / (Expense), net		 -0.08 0.09 0.02 0.04 0.14 -0.09 -0.04 0.04 0.01 0.01 0.12
Basic Earnings per Share		 ($0.48) ($0.47) ($0.56) ($0.54) ($0.60) ($0.50) ($0.36) ($0.51) ($0.49) ($0.51) ($0.52)
Weighted Average Basic Shares Outstanding		 44.98M 45.25M 55.57M 56.28M 57.26M 58.74M 85.43M 85.50M 85.73M 87.01M 102.80M
Diluted Earnings per Share		 ($0.48) ($0.47) ($0.56) ($0.54) ($0.60) ($0.50) ($0.36) ($0.51) ($0.49) ($0.51) ($0.52)
Weighted Average Diluted Shares Outstanding		 44.98M 45.25M 55.57M 56.28M 57.26M 58.74M 85.43M 85.50M 85.73M 87.01M 102.80M
Weighted Average Basic & Diluted Shares Outstanding		 54.77M 55.91M 55.93M 57.27M 57.30M 68.33M 68.42M 85.73M 85.75M 87.16M 87.35M

Annual Cash Flow Statements for Olema Pharmaceuticals

This table details how cash moves in and out of Olema Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 338 -325 9.89 45 71 -91
Net Cash From Operating Activities		 -20 -51 -82 -84 -104 -147
Net Cash From Continuing Operating Activities		 -20 -51 -82 -84 -104 -147
Net Income / (Loss) Continuing Operations		 -22 -71 -105 -97 -129 -162
Consolidated Net Income / (Loss)		 -22 -71 -105 -97 -129 -162
Depreciation Expense		 0.01 0.16 0.36 0.38 0.39 0.49
Amortization Expense		 0.00 0.28 0.00 0.00 -8.18 -6.29
Non-Cash Adjustments To Reconcile Net Income		 3.75 17 19 13 24 19
Changes in Operating Assets and Liabilities, net		 -1.51 2.83 3.02 -0.59 9.16 2.78
Net Cash From Investing Activities		 -0.06 -275 91 -4.85 -94 -156
Net Cash From Continuing Investing Activities		 -0.06 -275 91 -4.85 -94 -156
Purchase of Property, Plant & Equipment		 -0.06 -1.58 -0.36 0.00 -0.16 0.00
Purchase of Investments		 0.00 -487 -214 -256 -395 -501
Sale and/or Maturity of Investments		 0.00 213 306 251 302 345
Net Cash From Financing Activities		 358 1.39 0.48 133 269 211
Net Cash From Continuing Financing Activities		 358 1.39 0.48 133 269 211
Issuance of Debt		 3.00 - - - 0.00 208
Issuance of Common Equity		 221 0.72 0.33 131 267 -5.48
Other Financing Activities, net		 0.73 0.67 0.15 2.63 1.67 8.39

Quarterly Cash Flow Statements for Olema Pharmaceuticals

This table details how cash moves in and out of Olema Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 82 -49 -35 -17 19 104 -89 1.83 -17 13 4.25
Net Cash From Operating Activities		 -23 -18 -23 -28 -27 -26 -44 -30 -35 -38 -46
Net Cash From Continuing Operating Activities		 -23 -18 -23 -28 -27 -26 -44 -30 -35 -38 -46
Net Income / (Loss) Continuing Operations		 -22 -27 -31 -30 -35 -34 -30 -44 -42 -46 -53
Consolidated Net Income / (Loss)		 -22 -27 -31 -30 -35 -34 -30 -44 -42 -46 -53
Depreciation Expense		 0.09 0.09 0.09 0.09 0.10 0.12 0.13 0.13 0.04 0.19 0.12
Non-Cash Adjustments To Reconcile Net Income		 3.25 2.40 2.58 4.08 3.91 4.99 2.26 2.96 2.92 11 8.86
Changes in Operating Assets and Liabilities, net		 -4.58 5.80 4.80 -1.35 3.53 2.18 -16 11 4.73 3.21 -1.88
Net Cash From Investing Activities		 -25 -31 -20 -4.88 46 -114 -45 34 17 -162 4.53
Net Cash From Continuing Investing Activities		 -25 -31 -20 -4.88 46 -114 -45 34 17 -162 4.53
Purchase of Investments		 -96 -85 -76 -82 -47 -189 -143 -33 -72 -253 -70
Sale and/or Maturity of Investments		 71 54 56 77 93 75 98 67 89 91 74
Net Cash From Financing Activities		 131 0.52 8.82 16 0.09 244 0.22 -2.52 0.04 214 46
Net Cash From Continuing Financing Activities		 131 0.52 8.82 16 0.09 244 0.22 -2.52 0.04 214 46
Repurchase of Common Equity		 - - 0.00 - - - -0.01 -6.50 - - 0.00
Issuance of Common Equity		 130 0.32 7.90 16 - 244 0.00 0.75 - -6.23 42
Other Financing Activities, net		 0.87 0.21 0.92 0.07 0.09 0.59 0.24 0.23 -6.47 14 3.79

Annual Balance Sheets for Olema Pharmaceuticals

This table presents Olema Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 343 296 216 277 451 533
Total Current Assets		 342 291 209 267 438 515
Cash & Equivalents		 339 14 24 69 139 48
Short-Term Investments		 0.00 273 181 193 295 457
Prepaid Expenses		 3.59 3.44 4.48 4.71 4.39 10
Plant, Property, & Equipment, net		 0.08 1.47 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.51 3.79 6.75 10 13 18
Other Noncurrent Operating Assets		 0.51 3.79 6.75 10 13 18
Total Liabilities & Shareholders' Equity		 343 296 216 277 451 533
Total Liabilities		 4.59 11 18 23 42 55
Total Current Liabilities		 4.59 9.02 17 22 42 52
Accounts Payable		 0.72 0.02 0.37 2.70 4.46 9.25
Other Current Liabilities		 3.87 9.00 16 19 37 43
Total Noncurrent Liabilities		 0.00 2.36 1.55 1.43 0.26 3.07
Long-Term Debt		 - - - - 0.00 3.00
Other Noncurrent Operating Liabilities		 - 2.36 1.55 1.43 0.26 0.07
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 338 285 198 254 409 479
Total Preferred & Common Equity		 338 285 198 254 409 479
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 338 285 198 254 409 479
Common Stock		 371 389 408 559 844 1,075
Retained Earnings		 -33 -104 -209 -306 -435 -598
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.15 -1.81 0.35 0.14 0.62

Quarterly Balance Sheets for Olema Pharmaceuticals

This table presents Olema Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 178 293 264 255 230 410 382 352 531
Total Current Assets		 172 282 252 242 218 397 368 334 513
Cash & Equivalents		 35 117 34 17 36 51 52 35 53
Short-Term Investments		 132 159 215 222 179 342 309 294 453
Prepaid Expenses		 4.07 5.11 3.11 3.08 3.23 3.96 5.81 5.37 7.88
Plant, Property, & Equipment, net		 1.27 1.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 4.84 9.74 12 12 12 13 14 18 17
Other Noncurrent Operating Assets		 4.84 9.74 12 12 12 13 14 18 17
Total Liabilities & Shareholders' Equity		 178 293 264 255 230 410 382 352 531
Total Liabilities		 16 18 27 27 31 26 37 45 50
Total Current Liabilities		 15 16 26 27 31 26 33 42 47
Accounts Payable		 1.63 2.21 7.66 4.35 2.69 0.15 0.93 3.47 3.72
Other Current Liabilities		 0.80 0.92 19 22 28 26 32 38 43
Total Noncurrent Liabilities		 1.21 1.70 1.15 0.86 0.56 0.12 3.60 3.31 3.00
Long-Term Debt		 - - - - - - 3.00 3.00 3.00
Other Noncurrent Operating Liabilities		 1.21 1.70 1.15 0.86 0.56 0.12 0.60 0.31 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 162 275 236 227 199 383 345 307 480
Total Preferred & Common Equity		 162 275 236 227 199 383 345 307 480
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 162 275 236 227 199 383 345 307 480
Common Stock		 419 554 573 594 600 849 854 858 1,132
Retained Earnings		 -257 -279 -337 -367 -402 -465 -509 -551 -651
Accumulated Other Comprehensive Income / (Loss)		 -0.52 -0.24 -0.01 -0.12 0.46 0.42 0.31 0.53 -0.46

Annual Metrics And Ratios for Olema Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Olema Pharmaceuticals' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 40,287,641.00 40,455,427.00 54,769,800.00 - 85,754,086.00
DEI Adjusted Shares Outstanding		 0.00 0.00 40,287,641.00 40,455,427.00 54,769,800.00 - 85,754,086.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.76 -2.59 -1.76 - -1.89
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -3.03 -15 -50 -75 -73 -100 -125
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -28.94% -24.35% -25.98%
Earnings before Interest and Taxes (EBIT)		 -4.32 -22 -72 -107 -105 -142 -179
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.32 -22 -71 -107 -105 -142 -184
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -15 -48 -71 -72 -82 -126
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -0.41 -2.68 -6.88 -7.91 -25 -24
Increase / (Decrease) in Invested Capital		 0.00 -0.41 -2.27 -4.19 -1.04 -17 1.24
Book Value per Share		 $0.00 $48.16 $7.06 $4.88 $4.64 $7.14 $5.58
Tangible Book Value per Share		 $0.00 $48.16 $7.06 $4.88 $4.64 $7.14 $5.58
Total Capital		 0.00 338 285 198 254 409 482
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 3.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 3.00
Net Debt		 0.00 -339 -287 -204 -262 -434 -502
Capital Expenditures (CapEx)		 0.00 0.06 1.58 0.36 -0.01 0.16 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -1.00 -5.58 -12 -17 -37 -42
Debt-free Net Working Capital (DFNWC)		 0.00 338 282 192 245 397 464
Net Working Capital (NWC)		 0.00 338 282 192 245 397 464
Net Nonoperating Expense (NNE)		 1.29 7.05 21 30 23 30 37
Net Nonoperating Obligations (NNO)		 0.00 -339 -287 -204 -262 -434 -502
Total Depreciation and Amortization (D&A)		 0.00 0.01 0.44 0.36 0.38 0.39 -5.80
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.80) ($2.62) ($2.14) ($2.20) ($1.87)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 39.52M 40.00M 45.25M 58.74M 87.01M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.80) ($2.62) ($2.14) ($2.20) ($1.87)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 39.52M 40.00M 45.25M 58.74M 87.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 40.35M 40.63M 55.91M 68.33M 87.16M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.03 -15 -50 -75 -73 -100 -125
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Olema Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Olema Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 41,352,381.00 54,769,800.00 55,914,741.00 55,933,827.00 57,266,358.00 - 68,333,065.00 68,421,277.00 85,728,492.00 85,754,086.00 87,156,961.00
DEI Adjusted Shares Outstanding		 41,352,381.00 54,769,800.00 55,914,741.00 55,933,827.00 57,266,358.00 - 68,333,065.00 68,421,277.00 85,728,492.00 85,754,086.00 87,156,961.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.52 -0.49 -0.55 -0.54 -0.60 - -0.44 -0.64 -0.49 -0.54 -0.61
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 -0.34% -11.75% -16.08% -55.00% -60.25% -21.53% -1.61% -42.81% -22.56% - -66.01%
EBIT Growth		 -0.34% -11.68% -15.99% -54.72% -60.04% -21.56% -1.72% -42.81% -22.36% - -65.74%
NOPAT Growth		 -0.52% -11.75% -16.00% -55.22% -61.17% -20.88% -1.56% -42.75% -21.95% - -66.28%
Net Income Growth		 5.36% -2.27% -9.49% -51.19% -60.71% -25.38% 1.88% -44.11% -22.17% - -74.70%
EPS Growth		 15.79% 27.69% 20.00% -10.20% -25.00% -6.38% 35.71% 5.56% 18.33% - -44.44%
Operating Cash Flow Growth		 -26.41% 6.27% -15.23% -24.59% -18.78% -42.26% -87.18% -8.45% -27.80% - -4.57%
Free Cash Flow Firm Growth		 -18.64% -36.30% -78.58% -27.06% 37.10% 57.90% -24.41% -82.67% -140.77% - -0.58%
Invested Capital Growth		 63.95% -15.08% -15.30% -103.74% -797.11% -217.52% 26.89% -14.54% -16.53% - -136.29%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 -8.28% -29.59% -13.23% 2.45% -11.95% 1.72% 5.33% -37.11% 3.93% - -15.76%
EBIT Q/Q Growth		 -8.21% -29.47% -13.19% 2.42% -11.92% 1.66% 5.28% -36.99% 4.10% - -15.57%
NOPAT Q/Q Growth		 -8.06% -30.31% -12.90% 2.36% -12.20% 2.27% 5.15% -37.25% 4.15% - -15.78%
Net Income Q/Q Growth		 -7.00% -24.51% -15.68% 1.90% -13.74% 2.86% 9.47% -44.08% 3.58% - -15.26%
EPS Q/Q Growth		 2.04% 2.08% -19.15% 3.57% -11.11% 16.67% 28.00% -41.67% 3.92% - -1.96%
Operating Cash Flow Q/Q Growth		 -2.84% 18.77% -27.17% -17.28% 1.96% 2.71% -67.32% 32.05% -15.54% - -19.99%
Free Cash Flow Firm Q/Q Growth		 -42.27% -4.01% -10.38% 22.21% 29.56% 30.39% -226.18% -14.21% 7.16% - 22.94%
Invested Capital Q/Q Growth		 69.85% -347.76% -60.00% 5.67% -32.75% -58.48% 63.16% -47.78% -35.06% - 8.41%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 91.81% 88.29% 90.23% 90.72% 92.19% 91.06% 87.04% 91.55% 92.05% - 91.75%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -38.98% -42.82% -48.31% -56.40% -51.76% -39.07% -41.59% -49.72% -59.22% - -42.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -38.98% -42.82% -48.31% -56.40% -51.76% -39.07% -41.59% -49.72% -59.22% - -42.86%
Return on Equity Simple (ROE_SIMPLE)		 -34.91% 0.00% -42.04% 0.00% 0.00% 0.00% -33.61% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 -21 -24 -23 -26 -26 -24 -34 -32 -35 -41
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.07% -2.35% -3.19% -3.40% -3.34% -2.25% -1.86% -3.44% -3.74% - -2.79%
Return On Investment Capital (ROIC_SIMPLE)		 - -8.39% -10.17% -10.33% -13.24% -6.29% -6.37% -9.62% -10.34% -7.28% -8.40%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -23 -30 -34 -33 -37 -37 -35 -48 -46 -50 -58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -23 -30 -34 -33 -37 -37 -35 -48 -46 -50 -58
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.86 3.03 2.68 2.66 3.44 0.82 0.67 0.84 2.73 - 2.70
Price to Tangible Book Value (P/TBV)		 1.86 3.03 2.68 2.66 3.44 0.82 0.67 0.84 2.73 - 2.70
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 - 0.01
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 - 0.01
Financial Leverage		 -1.01 -1.03 -1.06 -1.05 -1.04 -1.05 -1.04 -1.04 -1.07 - -1.04
Leverage Ratio		 1.06 1.09 1.12 1.11 1.10 1.10 1.09 1.11 1.15 - 1.09
Compound Leverage Factor		 0.98 0.96 1.01 1.01 1.02 1.00 0.95 1.02 1.06 - 1.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.86% 0.97% - 0.62%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.86% 0.97% - 0.62%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.14% 99.03% - 99.38%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 - -0.01
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.29 1.98 - 2.50
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 - -0.01
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.03 - -0.02
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.26 2.82 - 3.56
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.03 - -0.02
Altman Z-Score		 16.84 19.16 12.68 11.82 11.12 4.21 5.10 3.53 9.58 - 14.52
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 17.66 12.33 9.61 9.13 7.10 10.50 15.22 11.09 8.03 - 10.88
Quick Ratio		 17.34 12.11 9.49 9.01 7.00 10.40 15.07 10.91 7.90 - 10.71
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -19 -20 -22 -17 -12 -8.53 -28 -32 -29 -36 -28
Operating Cash Flow to CapEx		 0.00% 0.00% -15,356.86% -459,250.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.77 -7.91 -13 -12 -16 -25 -9.26 -14 -18 -24 -22
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 3.13 -1.04 -1.68 -6.08 -14 -17 3.40 -1.74 -2.62 1.24 -13
Enterprise Value (EV)		 234 507 384 366 469 -100 -136 -67 513 - 797
Market Capitalization		 511 768 633 605 684 334 257 291 839 - 1,300
Book Value per Share		 $6.65 $4.64 $4.23 $4.06 $3.47 $7.14 $5.61 $5.05 $3.59 $5.58 $5.51
Tangible Book Value per Share		 $6.65 $4.64 $4.23 $4.06 $3.47 $7.14 $5.61 $5.05 $3.59 $5.58 $5.51
Total Capital		 275 254 236 227 199 409 383 348 310 482 483
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.00 3.00 3.00 3.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.00 3.00 3.00 3.00
Net Debt		 -277 -262 -249 -239 -215 -434 -393 -359 -326 -502 -502
Capital Expenditures (CapEx)		 -0.01 0.00 0.15 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -17 -23 -23 -27 -37 -22 -27 -36 -42 -39
Debt-free Net Working Capital (DFNWC)		 266 245 226 216 187 397 371 335 293 464 466
Net Working Capital (NWC)		 266 245 226 216 187 397 371 335 293 464 466
Net Nonoperating Expense (NNE)		 5.16 5.48 6.93 6.91 8.22 7.83 5.98 10 10 11 12
Net Nonoperating Obligations (NNO)		 -277 -262 -249 -239 -215 -434 -393 -359 -326 -502 -502
Total Depreciation and Amortization (D&A)		 0.09 0.09 0.09 0.09 0.10 0.12 0.13 0.13 0.04 0.19 0.12
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.48) ($0.47) ($0.56) ($0.54) ($0.60) ($0.50) ($0.36) ($0.51) ($0.49) ($0.51) ($0.52)
Adjusted Weighted Average Basic Shares Outstanding		 44.98M 45.25M 55.57M 56.28M 57.26M 58.74M 85.43M 85.50M 85.73M 87.01M 102.80M
Adjusted Diluted Earnings per Share		 ($0.48) ($0.47) ($0.56) ($0.54) ($0.60) ($0.50) ($0.36) ($0.51) ($0.49) ($0.51) ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding		 44.98M 45.25M 55.57M 56.28M 57.26M 58.74M 85.43M 85.50M 85.73M 87.01M 102.80M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 54.77M 55.91M 55.93M 57.27M 57.30M 68.33M 68.42M 85.73M 85.75M 87.16M 87.35M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -21 -24 -23 -26 -26 -24 -34 -32 -35 -41
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Olema Pharmaceuticals (OLMA) shows a biotech-style profile in these quarters: little to no reported revenue, meaningful R&D spend, ongoing net losses, but active financing that provides liquidity runway. Here are the most notable trends across the last four years of quarterly data available (2023–2025):

  • In Q4 2025, Olema secured substantial financing inflows: Net cash from financing activities was about $213.6 million, driven by new debt issuance of roughly $205.4 million. This provides a large liquidity runway to support ongoing R&D and clinical activities.
  • The Q3 2025 balance sheet confirms a strong equity base, with Total Equity around $307.5 million and Total Liabilities of about $44.97 million, indicating a solid equity cushion relative to liabilities.
  • Olema carries a large liquidity buffer from short-term investments in the Q3 2025 balance sheet, with Short-Term Investments around $293.7 million, helping to support liquidity while operations remain cash-intensive.
  • Total revenue is effectively zero across the quarters shown (e.g., Q4 2025 and several prior quarters), which is typical for a late-stage biotech awaiting product approvals or commercialization.
  • R&D and SG&A expenses remain very high (e.g., Q4 2025 RD expense about $43.22 million; other quarters show similar high levels), underscoring ongoing burn tied to development activities.
  • Long-term debt is relatively small in the latest periods (e.g., about $3.0 million in Q3 2025), indicating limited leverage at this stage.
  • Net income is consistently negative across quarters, with Q4 2025 net income at -$46.06 million, reflecting ongoing losses from operations.
  • Cash flow from operating activities is negative in every quarter shown, signaling ongoing cash burn from core operations despite financing inflows.
05/14/26 04:44 PM ETAI Generated. May Contain Errors.

Olema Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Olema Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Olema Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$162.45 million in 2025, rising from -$4.32 million in 2019. The previous period was -$129.47 million in 2024. See Olema Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Olema Pharmaceuticals' total operating income in 2025 was -$178.70 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $178.70 million

Over the last 6 years, Olema Pharmaceuticals' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Olema Pharmaceuticals' total liabilities were at $54.87 million at the end of 2025, a 30.6% increase from 2024, and a 1,096.8% increase since 2020.

In the past 5 years, Olema Pharmaceuticals' cash and equivalents has ranged from $13.81 million in 2021 to $338.55 million in 2020, and is currently $48.30 million as of their latest financial filing in 2025.

Over the last 6 years, Olema Pharmaceuticals' book value per share changed from 0.00 in 2019 to 5.58 in 2025, a change of 558.1%.


Related Companies

Financial statements for NASDAQ:OLMA last updated on 5/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Millionaire warns: Move your money now
Larry Benedict, the hedge fund trader who generated $274 million in profits for clients and beat the S&P 500 b...
Brownstone Research | Sponsoredtc pixel
Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX
The Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...
InvestorPlace | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
You'll buy SpaceX at $1.75 trillion. Insiders bought at $20 billion.
Insiders bought SpaceX at $20 billion. Banks got in at $100 billion. By the time it hits your brokerage accoun...
Behind the Markets | Sponsoredtc pixel
The system holding the dollar together is gone…
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel